In pharyngeal carcinoma, Van Aarsen et al. demonstrated that blocking with an integrin αvβ6 antibody reduced TGF-β-induced SMAD2 phosphorylation, which resulted in diminished tumor growth and reduced invasive potential while an impact of the treatment on cell proliferation was not observed [37]. This evidence concerns the gene TGFB1 and neoplasm.